Galectin-9 Controls the Activity of DR3 (TNFRSF25) in Suppressing Immunity

Abstract TNFR superfamily members are cell surface glycoprotein receptors that are either induced and/or constitutively expressed on various immune cell types. Previously we have shown that the membrane proximal extracellular region of the TNFR superfamily member 4-1BB, interacts with Galectin-9, an...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of immunology (1950) Vol. 196; no. 1_Supplement; pp. 126 - 126.30
Main Authors Madireddi, Shravan, Eun, So-Young, Mehta, Amit K, Birta, Aruna, Zajonc, Dirk M, Nishi, Nozomu, Niki, Toshiro, Hirashima, Mitsuomi, Schreiber, Taylor H, Podack, Eckhard R, Croft, Michael
Format Journal Article
LanguageEnglish
Published 01.05.2016
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract TNFR superfamily members are cell surface glycoprotein receptors that are either induced and/or constitutively expressed on various immune cell types. Previously we have shown that the membrane proximal extracellular region of the TNFR superfamily member 4-1BB, interacts with Galectin-9, and in turn facilitates oligomerization and/or clustering of 4-1BB molecules on the cell surface in a manner that allows efficient signaling. Galectin-9 is a member of the beta-galactoside binding lectin family of proteins that contain homologous carbohydrate recognition domains and typically bind to specific glycans of a glycoprotein. Consequently, a search for other TNFR superfamily glycoproteins that might be regulated by Galectin-9 revealed an interaction with the extracellular region of DR3 (TNFRSF25). DR3 is expressed on conventional CD4+ T cells and CD4+ Foxp3+ Treg cells and acts as a stimulatory receptor when ligated. Functional studies in vitro showed that the stimulatory activity of DR3 was in part dependent on Galectin-9 in that Galectin-9−/− CD4 T cells were less responsive when DR3 was ligated. Furthermore, in vivo, where an agonist of DR3 can transiently induce Treg cell expansion in wild-type mice, we found that this effect of anti-DR3 was significantly lost in Galectin-9−/− mice. Additionally, in EAE as well as Asthma models, where an agonist of DR3 can suppress disease via control of CD4+ Foxp3+ Treg cells, we found that this protective effect of anti-DR3 was lost in Galectin-9−/− mice. Thus, our data demonstrate a novel function of Galectin-9 in facilitating signaling through DR3, and suggest that Galectin-9 may allow DR3 to oligomerize and/or cluster in a manner that allows efficient engagement of intracellular signaling pathways.
ISSN:0022-1767
1550-6606
DOI:10.4049/jimmunol.196.Supp.126.30